Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning.

Volume: 162, Pages: 195 - 202
Published: Jan 1, 2003
Abstract
A prospective analysis was performed in 124 non-small cell lung cancer patients to determine the role of F-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) for molecular (metabolic) staging (n=63), therapy monitoring after induction-chemotherapy (n=34), and conformai radiation treatment planning (n=27). Staging by FDG-PET was significantly more accurate than CT (p<0.00l) and changed therapeutic management in 52% of all patients....
Paper Details
Title
Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning.
Published Date
Jan 1, 2003
Volume
162
Pages
195 - 202
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.